GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (FRA:1JK) » Definitions » Research & Development

Apellis Pharmaceuticals (FRA:1JK) Research & Development : €304.2 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Apellis Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Apellis Pharmaceuticals's Research & Development for the three months ended in Mar. 2024 was €77.9 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €304.2 Mil.

Apellis Pharmaceuticals Research & Development Historical Data

The historical data trend for Apellis Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apellis Pharmaceuticals Research & Development Chart

Apellis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 198.87 246.54 372.47 365.55 324.97

Apellis Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 102.77 88.29 74.42 63.53 77.93

Apellis Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €304.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apellis Pharmaceuticals  (FRA:1JK) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Apellis Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of Apellis Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Apellis Pharmaceuticals (FRA:1JK) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (FRA:1JK) » Definitions » Research & Development
Comparable Companies
KRTX ABCZF IONS ASND EXEL IMVT ROIV HALO PCVX BBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
APLS:USA
Address
100 Fifth Avenue, Waltham, MA, USA, 02451
Website
https://www.apellis.com
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.

Apellis Pharmaceuticals (FRA:1JK) Headlines

No Headlines